Robin Fouquet
Primary Care · New Orleans, LANPI 1114536703
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 20 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Gilead at 26.5% of the total.
Across 20 payments — averaging $85.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$451
- AstraZeneca$229
- Otsuka America Pharmaceutical, Inc.$138
- AbbVie$125
- Teva Pharmaceuticals USA, Inc.$125
- Dexcom, Inc.$124
- plus $511 from 7 others
What the payments were for
- Food & beverage$1,703100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 5 | $451 |
| AstraZeneca(2 entities) | 2 | $229 |
| Otsuka America Pharmaceutical, Inc. | 2 | $138 |
| AbbVie | 1 | $125 |
| Teva Pharmaceuticals USA, Inc. | 1 | $125 |
| Dexcom, Inc. | 1 | $124 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $122 |
| Idorsia Pharmaceuticals US Inc | 1 | $120 |
| Agile Therapeutics, Inc. | 2 | $111 |
| Neurocrine Biosciences, Inc. | 1 | $104 |
| Pfizer | 1 | $19 |
| Organon | 1 | $18 |
| Exact Sciences | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,703 in reported general payments places this provider in the 70th percentile of 106 primary care providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fluticasone Propionate | 67 | $1,067 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 36 | $794 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 36 | $342 |
| Doxycycline Monohydrate | 11 | $164 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 15 | $159 |
| Montelukast Sodium | 22 | $151 |
| Mupirocin | 11 | $102 |
| Naproxen | 14 | $58 |
| Azithromycin | 12 | $34 |
Paid to pharmacies, not to this prescriber.
Other primary care in New Orleans
- Mia Schexnayder-DavisNew Orleans$10K
- Abby WalkerNew Orleans$3K
- Jacob RickollNew Orleans$3K
- Courtney GriffinNew Orleans$2K
- Amanda HillNew Orleans$1K
- Lucienne SimsNew Orleans$913
- Morgan JonesNew Orleans$738
- Lindsey DuffyNew Orleans$683
- Martha CossichNew Orleans$526
- Wendy TaylorShreveport$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.